An official website of the United States government
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Wells G, Coyle D, Cameron C, et al. Safety, Effectiveness, and Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2012 Apr 9.
| Stroke/SE | Major Bleeding | All-cause Mortality | Intracranial Bleeding | Major GI Bleeding | Myocardial Infarction | |
|---|---|---|---|---|---|---|
| Apixaban 5 mg b.i.d. | 0.76 (0.52 to 1.10) | 0.69 (0.50 to 0.94) | 0.89 (0.69 to 1.15) | 0.43 (0.22 to 0.82) | 0.85 (0.48 to 1.49) | 0.85 (0.46 to 1.56) |
| Dabigatran 110 mg b.i.d. | 0.93 (0.62 to 1.39) | 0.82 (0.59 to 1.12) | 0.91 (0.68 to 1.22) | 0.33 (0.14 to 0.79) | 1.11 (0.65 to 1.88) | 1.29 (0.68 to 2.43) |
| Dabigatran 150 mg b.i.d. | 0.66 (0.42 to 1.04) | 0.95 (0.70 to 1.29) | 0.89 (0.66 to 1.19) | 0.46 (0.22 to 0.98) | 1.52 (0.93 to 2.48) | 1.26 (0.67 to 2.39) |
| Rivaroxaban 20 mg q.d. | 0.81 (0.54 to 1.20) | 1.02 (0.75 to 1.39) | 0.82 (0.55 to 1.24) | 0.59 (0.31 to 1.12) | 1.50 (0.95 to 2.35) | 0.83 (0.47 to 1.47) |
b.i.d. = twice daily; CI = confidence interval; GI = gastrointestinal; GLMM = generalized linear mixed models; q.d. = once daily.
Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
Your browsing activity is empty.
Activity recording is turned off.
See more...
